by Panjasawatwong N, Avihingsanon A, Menétrey C, Ribeiro I, Salvadori N, Swanson A, Gillon J-Y, Tan S, Thanprasertsuk S, Thongsawat S, Cressey TR. Antimicrobial Agents and Chemotherapy 2024, 68: e00008-24. doi: 10.1128/aac.00008-24
Summary: Sofosbuvir plus ravidasvir is a novel direct acting antiviral treatment for hepatitis C (HCV) that was shown to be safe and efficacious in the STORM-C-1 trial. Sofosbuvir (400 mg) plus ravidasvir (200 mg) was administered orally once daily for 12 weeks to adults with chronic HCV infection but without cirrhosis, and for 24 weeks to those with compensated cirrhosis. The authors of this paper assessed the population pharmacokinetics of ravidasvir in 594 participants in a sub-study nested within the STORM-C-1 trial. There were no meaningful drug-drug interactions in participants living with HIV on antiretroviral treatment, and while several covariates impacted ravidasvir pharmacokinetics, the effect on ravidasvir exposures was not clinically relevant based on the reported efficacy data.
